ASOs bind specifically to their target RNAs and are widely used for drug target screening and design. With advanced molecular biology platforms, CD Formulation offers high-quality, customized, and large-scale ASO synthesis services.
Antisense oligonucleotides (ASOs) are lab-made strands of nucleotides, usually longer than 15 bases. They work by entering cells and attaching themselves to specific mRNA targets through complementary base pairing. This process, assisted by an enzyme called ribonuclease H1, ultimately leads to the suppression of the genes those mRNAs were meant to express. Upon binding to the target mRNA or precursor mRNA, ASOs regulate RNA function through several distinct mechanisms.
CD Formulation's platform not only customizes standard, unmodified ASOs but also produces complex ASOs that require multiple modifications.
We possess extensive expertise in chemical modification technology and capabilities, we can enhance the stability and resistance to nuclease degradation of antisense oligonucleotides through thio-modification.
Our team develops specialized assays for nucleic acid products and conducts quality studies, methodology validation, standard establishment, stability studies, and other services for new nucleic acid products. We can collaboratively establish quality standards for the production of nucleic acid products, as well as the content and scope of quality studies, tailored to customer objectives and in conjunction with assessments of drug efficacy and pharmacology.
We offer production services ranging from microgram to kilogram levels to meet the needs at every stage.
Types | Contents | Descriptions |
---|---|---|
PS-ASO | 2 OD | This can be utilized for cellular experiments. |
OMe-ASO | 2 OD | This can be utilized for both cellular and animal experiments. |
LNA-ASO | 2 OD | This can be utilized for cellular and animal experiments. |
Fig.1 Flow chart of ASOs preparation. (CD Formulation)
CD Formulation offers a customized platform for high-throughput synthesis of oligonucleic acids at an internationally advanced level. Our production center is capable of manufacturing a wide range of nucleic acids in single batches, ranging from micrograms to hundreds of grams and even kilograms. This capability meets the diverse needs of scientific research, development, and the screening of new drugs at various stages.
Synthesis Technology Platforms |
---|
Solid Phase Synthesis Technology Platform |
Enzymatic Synthesis Technology Platform |
Genetic Engineering Technology Platform |
Our quality control platform offers comprehensive process quality control, spanning from sequence design to final product testing, utilizing advanced synthesis technology and precise sequencing analysis. Our platform's automated processes not only enhance productivity but also minimize human error, resulting in highly consistent product quality.
Technology: Development of ASOs by chemical modification or bioconjugation technologies
Journal: Pharmaceutics
IF: 6.321
Published: 2021
Results:
Antisense oligonucleotide (ASO) technology utilizes short, single-stranded oligonucleotides to target RNA molecules, either promoting their degradation or blocking the binding of proteins such as cytokines. By chemically modifying or conjugating these ASOs, their behavior within the body can be improved, making them more effective and adaptable for various medical treatments. ASO-based therapies have been utilized to treat genetic disorders, cancer, and viral infections. Notably, ASOs can be rapidly developed for emerging viruses and their re-emerging variants.
Fig.2 Molecular mechanisms of action of ASOs. (Tarn W Y, et al., 2021)
CD Formulation offers customized synthetic ASOs services and is dedicated to supporting researchers and pharmaceutical companies in gene editing and therapeutic applications. Please feel free to contact us for assistance with your innovative drug development projects.
References